Data Insights

Pemafibrate by Kowa for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval

Pemafibrate is under clinical development by Kowa and currently in Phase II for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). According...

Likelihood of Approval and Phase Transition Success Rate Model - Pemafibrate in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)

Data Insights

Ripasudil hydrochloride hydrate by Kowa for Corneal Edema: Likelihood of Approval

Ripasudil hydrochloride hydrate is under clinical development by Kowa and currently in Phase III for Corneal Edema. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ripasudil Hydrochloride Hydrate in Corneal Edema

Data Insights

Pemafibrate + tofogliflozin by Kowa for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval

Pemafibrate + tofogliflozin is under clinical development by Kowa and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According...

Data Insights

Ripasudil hydrochloride hydrate by Kowa for Retinopathy Of Prematurity: Likelihood of Approval

Ripasudil hydrochloride hydrate is under clinical development by Kowa and currently in Phase II for Retinopathy Of Prematurity. According to...

Data Insights

Ripasudil hydrochloride hydrate by Kowa for Fuchs Endothelial Corneal Dystrophy (FECD): Likelihood of Approval

Ripasudil hydrochloride hydrate is under clinical development by Kowa and currently in Phase III for Fuchs Endothelial Corneal Dystrophy (FECD)....

Data Insights

K-161 by Kowa for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval

K-161 is under clinical development by Kowa and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - K-161 in Keratoconjunctivitis Sicca (Dry Eye)